RABEPRAZOLE

Only use when oral administration is not possible and in acute or severe attacks of:

• Active duodenal ulcer
• Active benign gastric ulcer
• Gastro-oesophageal reflux disease

• Reconstitute with 5 ml of water for injections. Dilute with normal saline to be used as an infusion
• Compatible with water for injections and sodium chloride 0.9% (normal saline) solutions only

• Hypersensitivity to rabeprazole

• Infection
• Insomnia, headache, dizziness
• Cough, pharyngitis, rhinitis
• Diarrhoea, vomiting, nausea, abdominal pain
• Constipation, flatulence
• Non-specific pain, back pain
• General weakness, influenza-like syndrome
• Stevens-Johnson syndrome
• Hepatic encephalopathy

• Atazanavir (reduced plasma concentration of atazanavir)

• Consult your doctor if signs of hypomagnesaemia such as fatigue, convulsions, intermittent muscular spasms (tetany) or dizziness occur

• Do not use

• Do not use

• Use with caution in severe hepatic dysfunction
• Risk of cross-sensitivity with other proton pump inhibitors or substituted benzimidazoles
• Serious hypomagnesaemia requiring discontinuation of rabeprazole and magnesium supplementation may occur after treatment for 3 months to 1 year. Signs include fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia